Roger Adsett Sells 2,444 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 2,444 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.95, for a total value of $161,181.80. Following the completion of the transaction, the chief operating officer now directly owns 147,666 shares of the company’s stock, valued at approximately $9,738,572.70. The trade was a 1.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total value of $312,159.36.

Insmed Price Performance

Shares of NASDAQ:INSM traded down $0.47 during trading on Friday, reaching $65.25. The stock had a trading volume of 3,087,759 shares, compared to its average volume of 1,881,810. The business has a fifty day moving average price of $71.29 and a 200-day moving average price of $72.44. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market cap of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. The firm’s revenue was up 18.1% on a year-over-year basis. During the same period last year, the business earned ($1.10) EPS. On average, equities analysts forecast that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on INSM shares. Bank of America boosted their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Truist Financial reissued a “buy” rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. boosted their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Darwin Global Management Ltd. purchased a new stake in shares of Insmed in the second quarter valued at approximately $237,076,000. Vestal Point Capital LP grew its holdings in Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after buying an additional 850,000 shares in the last quarter. Clearbridge Investments LLC increased its stake in shares of Insmed by 76.8% in the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after acquiring an additional 714,539 shares during the last quarter. Farallon Capital Management LLC purchased a new position in shares of Insmed during the 2nd quarter worth $38,056,000. Finally, Fred Alger Management LLC purchased a new position in shares of Insmed during the 2nd quarter worth $33,404,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.